| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL17RA |
| Uniprot No | Q96F46 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-320aa |
| 氨基酸序列 | LRLLDHRALV CSQPGLNCTV KNSTCLDDSW IHPRNLTPSS PKDLQIQLHF AHTQQGDLFP VAHIEWTLQT DASILYLEGA ELSVLQLNTN ERLCVRFEFL SKLRHHHRRW RFTFSHFVVD PDQEYEVTVH HLPKPIPDGD PNHQSKNFLV PDCEHARMKV TTPCMSSGSL WDPNITVETL EAHQLRVSFT LWNESTHYQI LLTSFPHMEN HSCFEHMHHI PAPRPEEFHQ RSNVTLTLRN LKGCCRHQVQ IQPFFSSCLN DCLRHSATVS CPEMPDTPEP IPDYMPLW |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL17RA重组蛋白的3篇参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Structural basis of receptor sharing by interleukin 17 cytokines*
**作者**：Chen Y. et al.
**摘要**：该研究通过X射线晶体学解析了IL17RA重组蛋白与IL-17A和IL-17F的复合物结构，揭示了IL17RA如何通过共享受体机制介导不同IL-17家族细胞因子的信号传导，为靶向IL17RA的抗体药物设计提供结构基础。
---
2. **文献名称**：*IL-17RA signaling amplifies antibody-induced arthritis through neutrophil recruitment*
**作者**：Gaffen S.L. et al.
**摘要**：研究利用重组IL17RA蛋白阻断实验，证明IL17RA在小鼠抗体诱导的关节炎模型中通过促进中性粒细胞浸润加剧炎症反应，表明靶向IL17RA可能成为自身免疫疾病的潜在治疗策略。
---
3. **文献名称**：*Recombinant IL-17RA extracellular domain inhibits TH17 responses in vitro and in vivo*
**作者**：Huang Q. et al.
**摘要**：该文献报道了重组IL17RA胞外段的表达与功能验证，证明其可通过竞争性结合IL-17A，抑制Th17细胞分化和炎性因子释放，并在实验性自身免疫性脑脊髓炎(EAE)模型中减轻神经炎症。
---
这些文献涵盖了IL17RA重组蛋白的结构解析、信号机制研究及治疗应用探索，可根据实际研究需求进一步查阅原文。
Interleukin-17 receptor A (IL17RA) is a key component of the IL-17 receptor family, playing a pivotal role in mediating inflammatory and immune responses. As a type I transmembrane protein, it consists of an extracellular domain, a single transmembrane region, and a cytoplasmic signaling domain. IL17RA serves as a common subunit for multiple IL-17 receptor complexes, including those binding IL-17A, IL-17F, and IL-17A/F heterodimers. Its activation triggers downstream signaling pathways such as NF-κB and MAPK, leading to the production of pro-inflammatory cytokines, chemokines, and antimicrobial peptides. This receptor is broadly expressed in epithelial, endothelial, and immune cells, linking innate and adaptive immunity.
Recombinant IL17RA protein is typically produced using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and functional integrity. The purified protein often includes fusion tags like Fc or His for enhanced stability and detection. Researchers utilize IL17RA recombinant proteins to study receptor-ligand interactions, screen therapeutic agents, and investigate autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. Its soluble form has shown potential as a decoy receptor to neutralize excessive IL-17 signaling in pathological conditions.
Recent studies highlight IL17RA's involvement in host defense against fungal and bacterial infections, as well as its dual role in promoting both tissue repair and chronic inflammation. The development of IL17RA-targeted biologics, including monoclonal antibodies and fusion proteins, has emerged as a promising strategy for immune-mediated disorders. Structural characterization of recombinant IL17RA has provided insights into its ligand-binding epitopes and dimerization mechanisms, facilitating the design of next-generation immunotherapies. Quality control of the recombinant protein typically involves SDS-PAGE, Western blot, and functional assays using IL-17-responsive cell lines to confirm bioactivity.
×
